4 unknown, 1 recruiting. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 4, Recruiting 1 |
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
Follow YY-20394: new trials by email Literature Review of YY-20394 trials Research Report on YY-20394
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Linperlisib, Camrelizumab, Pegaspargase - Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma | Phase 1 / Phase 2 | Recruiting | Beijing Tongren Hospital | 43 | 2024-04-14 | 2024-04-19 |
| A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma YY-20394 - Peripheral T/NK Cell Lymphoma (R/R PTCL) | Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 97 | 2022-05-01 | 2022-10-21 |
| A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma YY-20394 - Follicular Lymphoma | Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 140 | 2020-12-30 | 2020-05-07 |
| YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial YY-20394 - Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 28 | 2020-08-20 | 2020-08-05 |
| A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma YY-20394 - Lymphoma, Follicular | Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 123 | 2019-04-29 | 2020-05-11 |
Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Shanghai YingLi Pharmaceutical Co. Ltd. (4) · Beijing Tongren Hospital (1)
China (2) · United States (1)
Liang Wang, M.D. (1) · Ranjit Nair, MD. (1) · Zhiming Li, PHD (1)